| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
GB:0QIU
Novo Nordisk
|
Jun 17, 2026 | BUY |
Hold
+43.2% avg upside
28 analysts
|
$325.00
10.78% Upside
|
· |
|
ZLDPF
Zealand Pharma
|
Jun 16, 2026 | HOLD |
Buy
+91.6% avg upside
11 analysts
|
$46.04
2.84% Upside
|
· |
|
PFE
Pfizer
|
May 08, 2026 | HOLD |
Buy
+34.2% avg upside
45 analysts
|
$25.00
0.77% Downside
|
-1.8% |
|
GB:GSK
GlaxoSmithKline
|
May 05, 2026 | HOLD |
Hold
-2.9% avg upside
25 analysts
|
$2000.00
3.94% Upside
|
· |
|
LLY
Eli Lilly & Co
|
Apr 21, 2026 | HOLD |
Strong Buy
-10.5% avg upside
47 analysts
|
$1050.00
4.49% Downside
|
+21.9% |
|
NVO
Novo Nordisk
|
Mar 11, 2026 | BUY |
Buy
+168.8% avg upside
26 analysts
|
$47.00
8.85% Upside
|
+16.2% |
|
NVS
Novartis
|
Mar 06, 2026 | HOLD |
Hold
-7.5% avg upside
24 analysts
|
$141.00
4.10% Downside
|
-2.9% |
|
GSK
GlaxoSmithKline
|
Nov 25, 2025 | HOLD |
Hold
-13.9% avg upside
19 analysts
|
$43.00
15.08% Downside
|
+12.4% |
|
CH:NOVN
Novartis AG
|
Nov 18, 2025 | HOLD |
Buy
-9.8% avg upside
30 analysts
|
$92.00
22.13% Downside
|
· |
|
FR:SAN
Sanofi
|
May 16, 2025 | BUY |
Strong Buy
+32.9% avg upside
30 analysts
|
$120.00
61.89% Upside
|
· |
|
FR:EFG
OLYMPIQUE LYONNAIS GROUPE
|
Apr 01, 2025 | HOLD |
Hold
-16.7% avg upside
1 analyst
|
$1.60
16.65% Downside
|
· |
|
GB:TIG
Team Internet Group
|
Mar 24, 2025 | BUY |
Strong Buy
+375.0% avg upside
3 analysts
|
$100.00
149.94% Upside
|
· |
|
EL
The Estée Lauder Companies
|
Mar 24, 2025 | HOLD |
Buy
+20.4% avg upside
33 analysts
|
$60.00
29.35% Downside
|
+7.7% |
|
GB:0NZT
UCB SA
|
Apr 11, 2024 | BUY |
Buy
-15.2% avg upside
19 analysts
|
$130.00
48.02% Downside
|
· |
|
DE:MRK
Merck KGaA
|
Apr 16, 2021 | HOLD |
Buy
+2.2% avg upside
32 analysts
|
$150.00
12.77% Upside
|
· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.